Covid Reference

Page 54

54

|

CovidReference.com

tion of intense SARS-CoV-2 community transmission, strangers must not come together. Coronaviruses have come a long way (Weiss 2020) and will stay with us for a long time. Questions still abound: When will we be able to move freely around the world as we did before? Will we wear face masks for years? When we will see the impact of COVID-19 vaccines on the spread of the virus? How long will it take to vaccinate the majority of the global population? Will the immunity be long-lasting? Will the virus mutate, forcing new control measures and a new rush for a more effective vaccine? Will there be any nightlife event with densely packed people dancing and shouting and drinking in any city in the world anytime soon? Nobody knows. The French have an exquisitely precise formula to express unwillingness for living in a world you do not recognize: “Un monde de con!” Fortunately, we are slowly but surely capable of walking out of this “monde de con” thanks to a scientific community that is larger, stronger, and faster than at any time in history. (BTW, some politicians who were skeptical of science habe been ousted out of office. It is hight time!) As of today, we still do not know how long-lasting, how intense, and how deadly this pandemic will be. We are walking on moving ground and, in the coming months and years, we will need to continue to be flexible, resilient, and inventive, looking for and finding solutions nobody would have imagined just a few months ago. Sure enough though, science will lead the way out. If we could leap five years into the future and read the story of COVID-19, we would not believe our eyes.

References Adam D. A guide to R - the pandemic's misunderstood metric. Nature. 2020 Jul;583(7816):346348. PubMed: https://pubmed.gov/32620883. Full-text: https://doi.org/10.1038/d41586020-02009-w Adam DC, Wu P, Wong JY, et al. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. Nat Med. 2020 Sep 17. PubMed: https://pubmed.gov/32943787. Fulltext: https://doi.org/10.1038/s41591-020-1092-0 Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. Lancet. 2020 Sep 25;396(10259):1335-44. PubMed: https://pubmed.gov/32987007. Full-text: https://doi.org/10.1016/S0140-6736(20)32009-2 Andronico A, Kiem CT, Paireaux J, et al. Evaluating the impact of curfews and other measures on SARS-CoV-2 transmission in French Guiana. medRxiv 2020, posted 12 October. Fulltext: https://doi.org/10.1101/2020.10.07.20208314 Anonymous. Deutsche Box-Olympiamannschaft mit Coronavirus infiziert. Die Zeit 2020, published 12 September. Full-text: https://www.zeit.de/sport/2020-09/trainingslageroesterreich-deutsche-box-olympiamannschaft-coronavirus-infektion-quarantaene

Kamps – Hoffmann


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

References

1hr
pages 497-554

Management

10min
pages 491-496

Diagnosis and classification

11min
pages 484-490

Transplantation

4min
pages 472-473

Transmission

4min
pages 482-483

Pathophysiology and immunopathology

4min
pages 480-481

Natural course and risk factors for complications

2min
page 479

Epidemiology of COVID-19 in children

2min
page 478

Cancer

8min
pages 468-471

Immunosuppression (other than HIV

3min
pages 466-467

HIV infection

6min
pages 463-465

COPD and smoking

4min
pages 461-462

Hypertension and cardiovascular co-morbidities

14min
pages 452-458

Diabetes mellitus

4min
pages 459-460

References

6min
pages 447-451

Special situations in severe COVID-19

3min
pages 445-446

References

25min
pages 429-440

Spotlight: The situation in a German COVID-19 hospital

4min
pages 443-444

Outlook and Recommendations

1min
page 428

4. Immunomodulators

19min
pages 415-424

Other treatments for COVID-19 (with unknown or unproven mechanisms of action

5min
pages 425-427

3. Monoclonal Antibodies and Convalescent Plasma

13min
pages 408-414

2. Various antiviral agents

5min
pages 405-407

1. Inhibitors of the viral RNA synthesis

11min
pages 399-404

Monitoring, treatment options

3min
pages 391-392

Studies with objectifiable tests

3min
pages 389-390

Reactivations, reinfections

2min
page 366

Outcome

27min
pages 352-365

Clinical classification

1min
page 351

Laboratory findings

6min
pages 347-350

References

21min
pages 324-332

Asymptomatic cases

4min
pages 334-335

Radiology

6min
pages 321-323

Incubation period

1min
page 333

Symptoms

21min
pages 336-346

Diagnosis

36min
pages 303-320

References

55min
pages 277-302

Outlook

5min
pages 272-276

Single Vaccines

24min
pages 247-261

Coming vaccines

8min
pages 267-271

Special Topics

9min
pages 241-246

Approved Vaccines

2min
pages 223-224

References

21min
pages 211-222

Outlook

1min
page 210

Transmission

1min
page 187

Epidemiology

11min
pages 175-186

Summary – 13 February

1min
page 173

Genomic Structure and Variation

4min
pages 164-166

References

8min
pages 167-172

Origin and Evolution

4min
pages 158-159

Introduction

1min
page 174

History

4min
pages 154-155

References

20min
pages 136-152

Conclusion

1min
page 135

Introduction

31min
pages 117-133

Containment or mitigation of COVID-19?

1min
page 134

References

40min
pages 99-116

Outlook

1min
page 98

Prevention

3min
pages 96-97

End of Quarantine

1min
page 95

Transmission Event

26min
pages 82-94

References

31min
pages 54-68

Summary

1min
page 69

Routes of Transmission

16min
pages 73-81

Outlook

3min
pages 52-53

The 2020 Lockdowns

7min
pages 48-51

Person-to-person transmission

2min
page 72

Special Aspects of the Pandemic

15min
pages 38-46

The SARS-CoV-2 pandemic: Past and Future

2min
page 47
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.